Synlett 1991; 1991(4): 213-221
DOI: 10.1055/s-1991-20683
account
© Georg Thieme Verlag, Rüdigerstr. 14, 70469 Stuttgart, Germany. All rights reserved. This journal, including all individual contributions and illustrations published therein, is legally protected by copyright for the duration of the copyright period. Any use, exploitation or commercialization outside the narrow limits set by copyright legislation, without the publisher's consent, is illegal and liable to criminal prosecution. This applies in particular to photostat reproduction, copying, cyclostyling, mimeographing or duplication of any kind, translating, preparation of microfilms, and electronic data processing and storage.

Novel Serotonin-3 Receptor Antagonists

Terry Rosen* , Arthur A. Nagel, James P. Rizzi
  • *Pfizer Central Research, Groton, Connecticut 06340, USA
Further Information

Publication History

Publication Date:
07 March 2002 (online)

A structurally novel series of serotonin-3 (5-HT3) receptor antagonists is described. A computer pharmacophore model for ligands binding to this receptor has been developed and utilized to explain observed structure-activity relationships as well as demonstrated predictive utility. A novel azabicyclic 5-HT3 receptor ligand prototype [2-(4-amino-5-chloro-2-methoxybenzamidomethyl)-1-azabicyclo[2.2.2]oct-2-ene] has also been discovered, and its selective synthesis, which proceeds through a thermodynamically disfavored allylic azide, is described. 1. Introduction 2. Biological Assays - Definitions 3. Discovery of the Lead Structure 7 (3-[2-(Guanidinomethyl)-1,3-thiazol-4-yl]indole) and Approach to Its Modification 4. Definition and Application of an Initial Computer Pharmacophore Model for Selective 5-HT3 Receptor Ligands 5. Structure - Activity Relationship (SAR) Studies 6. Synthesis of a Novel Azabicyclic Prototype 7. Summary

    >